Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. [electronic resource]
Producer: 20190930Description: 96-108 p. digitalISSN:- 1872-7980
- Antineoplastic Agents -- chemistry
- Apoptosis -- drug effects
- Cell Line
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Docetaxel -- pharmacology
- Drug Resistance, Neoplasm -- drug effects
- Humans
- Male
- Molecular Structure
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Protein Binding
- Quinolines -- chemistry
- Reactive Oxygen Species -- metabolism
- Tubulin -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.